RIFAAT ELMALLAKH: Open Payments
NPI 1174595300 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$391,537 in 389 payments from 12 companies in 2025. Trend: 2023 $281,965 · 2024 $310,638 · 2025 $391,537
Speaker / faculty: $307,286Travel & lodging: $29,893Honoraria: $25,163Consulting: $20,896Food & beverage: $8,300
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 171 | $159,467 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 83 | $101,656 |
| Vanda Pharmaceuticals Inc. | 88 | $90,493 |
| Axsome Therapeutics, Inc. | 20 | $26,670 |
| ABBVIE INC. | 9 | $8,727 |
| E.R. Squibb & Sons, L.L.C. | 8 | $3,649 |
| Teva Pharmaceuticals USA, Inc. | 5 | $427 |
| Neurocrine BioSciences, Inc. | 1 | $139 |
| Alkermes, Inc. | 1 | $88 |
| Janssen Scientific Affairs, LLC | 1 | $78 |
Products named: CAPLYTA, ABILIFY MAINTENA, FANAPT, REXULTI, Auvelity, VRAYLAR, ABILIFY ASIMTUFII, COBENFY.
Industry payments across KY — which companies pay providers there.
